DOCSLIB.ORG

ABL Antibody (Y251) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap3018d

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ABL Antibody (Y251) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap3018d 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 ABL Antibody (Y251) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP3018d Specification ABL Antibody (Y251) - Product Information Application WB,E Primary Accession P00519 Other Accession P42684 Reactivity Human Host Rabbit Clonality Polyclonal Isotype Rabbit IgG ABL Antibody (Y251) - Additional Information Gene ID 25 Other Names Abelson tyrosine-protein kinase 1, Abelson murine leukemia viral oncogene homolog 1, Tyrosine-protein kinase ABL1, Western blot analysis of anti-ABL1 Antibody Proto-oncogene c-Abl, , p150, ABL, JTK7 (Cat.#AP3018d) in A2058 cell line lysates (35ug/lane). ABL1(arrow) was detected using Target/Specificity the purified Pab. This ABL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide corresponding to amino acid ABL Antibody (Y251) - Background residues between 220-249aa of human ABL1(P00519). Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to Dilution cell growth and survival such as cytoskeleton WB~~1:1000 remodeling in response to extracellular stimuli, cell motility and adhesion, receptor Format endocytosis, autophagy, DNA damage Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This response and apoptosis. Coordinates actin antibody is purified through a protein A remodeling through tyrosine phosphorylation column, followed by peptide affinity of proteins controlling cytoskeleton dynamics purification. like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); Storage DBN1, DBNL, CTTN, RAPH1 and ENAH (involved Maintain refrigerated at 2-8°C for up to 2 in signaling); or MAPT and PXN weeks. For long term storage store at -20°C (microtubule-binding proteins). in small aliquots to prevent freeze-thaw Phosphorylation of WASF3 is critical for the cycles. stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell Precautions adhesion and motility through phosphorylation ABL Antibody (Y251) is for research use of key regulators of these processes such as only and not for use in diagnostic or BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. therapeutic procedures. Phosphorylates multiple receptor tyrosine Page 1/4 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 kinases and more particularly promotes ABL Antibody (Y251) - Protein Information endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and Name ABL1 modulates the endocytosis of activated B-cell receptor complexes. Other substrates which Synonyms ABL, JTK7 are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 Function Non-receptor tyrosine-protein kinase that regulates the CBL family of ubiquitin ligases plays a role in many key processes linked to that drive receptor down-regulation and actin cell growth and survival such as remodeling. Phosphorylation of CBL leads to cytoskeleton remodeling in response to increased EGFR stability. Involved in late-stage extracellular stimuli, cell motility and autophagy by regulating positively the adhesion, receptor endocytosis, autophagy, trafficking and function of lysosomal DNA damage response and apoptosis. components. ABL1 targets to mitochondria in Coordinates actin remodeling through response to oxidative stress and thereby tyrosine phosphorylation of proteins mediates mitochondrial dysfunction and cell controlling cytoskeleton dynamics like death. ABL1 is also translocated in the nucleus WASF3 (involved in branch formation); where it has DNA-binding activity and is ANXA1 (involved in membrane anchoring); involved in DNA-damage response and DBN1, DBNL, CTTN, RAPH1 and ENAH apoptosis. Many substrates are known (involved in signaling); or MAPT and PXN mediators of DNA repair: DDB1, DDB2, ERCC3, (microtubule-binding proteins). ERCC6, RAD9A, RAD51, RAD52 or WRN. Phosphorylation of WASF3 is critical for the Activates the proapoptotic pathway when the stimulation of lamellipodia formation and DNA damage is too severe to be repaired. cell migration. Involved in the regulation of Phosphorylates TP73, a primary regulator for cell adhesion and motility through this type of damage- induced apoptosis. phosphorylation of key regulators of these Phosphorylates the caspase CASP9 on 'Tyr-153' processes such as BCAR1, CRK, CRKL, and regulates its processing in the apoptotic DOK1, EFS or NEDD9. Phosphorylates response to DNA damage. Phosphorylates multiple receptor tyrosine kinases and more PSMA7 that leads to an inhibition of particularly promotes endocytosis of EGFR, proteasomal activity and cell cycle transition facilitates the formation of neuromuscular synapses through MUSK, inhibits blocks. ABL1 acts also as a regulator of PDGFRB-mediated chemotaxis and multiple pathological signaling cascades during modulates the endocytosis of activated infection. Several known B-cell receptor complexes. Other substrates tyrosine-phosphorylated microbial proteins which are involved in endocytosis have been identified as ABL1 substrates. This regulation are the caveolin (CAV1) and is the case of A36R of Vaccinia virus, Tir RIN1. Moreover, ABL1 regulates the CBL (translocated intimin receptor) of pathogenic family of ubiquitin ligases that drive E.coli and possibly Citrobacter, CagA receptor down-regulation and actin (cytotoxin- associated gene A) of H.pylori, or remodeling. Phosphorylation of CBL leads to AnkA (ankyrin repeat-containing protein A) of increased EGFR stability. Involved in A.phagocytophilum. Pathogens can highjack late-stage autophagy by regulating ABL1 kinase signaling to reorganize the host positively the trafficking and function of actin cytoskeleton for multiple purposes, like lysosomal components. ABL1 targets to facilitating intracellular movement and host mitochondria in response to oxidative stress cell exit. Finally, functions as its own regulator and thereby mediates mitochondrial through autocatalytic activity as well as dysfunction and cell death. In response to through phosphorylation of its inhibitor, ABI1. oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717' ABL Antibody (Y251) - References (PubMed:<a href="http://www.uniprot.org/c itations/28428613" Shtivelman E.,et al.Cell 47:277-284(1986). target="_blank">28428613</a>). ABL1 is Fainstein E.,et al.Oncogene also translocated in the nucleus where it 4:1477-1481(1989). Chissoe S.L.,et has DNA-binding activity and is involved in Page 2/4 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 DNA-damage response and apoptosis. Many al.Genomics 27:67-82(1995). Humphray S.J.,et substrates are known mediators of DNA al.Nature 429:369-374(2004). Mural R.J.,et repair: DDB1, DDB2, ERCC3, ERCC6, al.Submitted (JUL-2005) to the RAD9A, RAD51, RAD52 or WRN. Activates EMBL/GenBank/DDBJ databases. the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner. Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity (By similarity). Cellular Location Cytoplasm, cytoskeleton. Nucleus. Mitochondrion. Note=Shuttles between the nucleus and cytoplasm depending on environmental signals. Sequestered into the cytoplasm through interaction with 14-3-3 proteins. Localizes to mitochondria in response to oxidative stress (By similarity). Tissue Location Widely expressed. ABL Antibody (Y251) - Protocols Provided below are standard protocols that you may find useful for product applications. • Western Blot Page 3/4 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 • Blocking Peptides • Dot Blot • Immunohistochemistry • Immunofluorescence • Immunoprecipitation • Flow Cytomety • Cell Culture Page 4/4 Powered by TCPDF (www.tcpdf.org).
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Hypermethylation of RAD9A Intron 2 in Childhood Cancer Patients, Leukemia and Tumor Cell Lines Suggest a Role for Oncogenic Transformation
    Hypermethylation of RAD9A intron 2 in childhood cancer patients, leukemia and tumor cell lines suggest a role for oncogenic transformation Danuta Galetzka ( [email protected] ) Johannes Gutenberg Universitat Mainz https://orcid.org/0000-0003-1825-9136 Julia Boeck Institute of Human Genetics, Julius Maximilians University Würzburg Marcus Dittrich Bioinformatics Department Julius-Maximilians-Universitat Wurzburg Olesja Sinizyn Department of Radiation Oncology and Radiations Therapy , University Medical Centre, Mainz Marco Ludwig DRK Medical Centre Alzey Heidi Rossmann Institute of Clinical Chemistry and Laboratory Medicine, University Medical Centre, Mainz Claudia Spix German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Mainz Markus Radsak Departement of Hematology, University Medical Centre, Mainz Peter Scholz-Kreisel Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Mainz Johanna Mirsch Radiation Biology and DNA Repair, Technical University, Darmstadt Matthias Linke Institute of Human Genetics, University Medical Centre, Mainz Walburgis Brenner Departement of Obsterics and Womans Health, University Medical Centre, Mainz Manuela Marron Leibniz Institute for Prevention Research and Epidemiology, BIPS, Bremen Alicia Poplawski Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Mainz Dirk Prawitt Center for Pediatrics and Adolescent Medicine, University Medical Centre, Mainz Thomas Haaf Institute of Human Genetics, Julius Maximilians University, Würzburg Heinz Schmidberger Department of Radiation Oncology and Radiation Therapy, University Centre, Mainz Research article Keywords: RAD9A, childhood cancer, hypermethylation, normal body cells, somatic mosaicism, leukemia Posted Date: August 12th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-55470/v1 Page 1/22 License: This work is licensed under a Creative Commons Attribution 4.0 International License.
    [Show full text]
  • HUS1 Regulates in Vivo Responses to Genotoxic Chemotherapies
    Oncogene (2016) 35, 662–669 © 2016 Macmillan Publishers Limited All rights reserved 0950-9232/16 www.nature.com/onc SHORT COMMUNICATION HUS1 regulates in vivo responses to genotoxic chemotherapies G Balmus1, PX Lim1, A Oswald1, KR Hume1,2, A Cassano1, J Pierre1, A Hill1, W Huang3, A August3, T Stokol4, T Southard1 and RS Weiss1 Cells are under constant attack from genotoxins and rely on a multifaceted DNA damage response (DDR) network to maintain genomic integrity. Central to the DDR are the ATM and ATR kinases, which respond primarily to double-strand DNA breaks (DSBs) and replication stress, respectively. Optimal ATR signaling requires the RAD9A-RAD1-HUS1 (9-1-1) complex, a toroidal clamp that is loaded at damage sites and scaffolds signaling and repair factors. Whereas complete ATR pathway inactivation causes embryonic lethality, partial Hus1 impairment has been accomplished in adult mice using hypomorphic (Hus1neo) and null (Hus1Δ1) Hus1 alleles, and here we use this system to define the tissue- and cell type-specific actions of the HUS1-mediated DDR in vivo. Hus1neo/Δ1 mice showed hypersensitivity to agents that cause replication stress, including the crosslinking agent mitomycin C (MMC) and the replication inhibitor hydroxyurea, but not the DSB inducer ionizing radiation. Analysis of tissue morphology, genomic instability, cell proliferation and apoptosis revealed that MMC treatment caused severe damage in highly replicating tissues of mice with partial Hus1 inactivation. The role of the 9-1-1 complex in responding to MMC was partially ATR-independent, as a HUS1 mutant that was proficient for ATR-induced checkpoint kinase 1 phosphorylation nevertheless conferred MMC hypersensitivity.
    [Show full text]
  • Rabbit Anti-Phospho-C-Abl-SL4086R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-phospho-c-Abl SL4086R-FITC Product Name: Anti-phospho-c-Abl(Tyr276)/FITC Chinese Name: FITC标记的磷酸化非受体酪氨酸激酶c-Abl抗体 Abelson Murine Leukemia Viral Oncogene Homolog 1; Abelson murine leukemia viral v abl oncogene homolog 1; Abl 1; ABL; Abl protein; Abl1; Bcr/c abl oncogene protein; Alias: JTK 7; JTK7; p150 ; Proto oncogene tyrosine protein kinase ABL1; Transformation gene oncogene ABL; v abl Abelson murine leukemia viral oncogene homolog 1; v abl. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Dog,Pig,Cow,Horse,Rabbit, IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 126kDa Cellular localization: The cell membrane Form: Lyophilized or Liquid Concentration: 1mg/ml KLHwww.sunlongbiotech.com conjugated Synthesised phosphopeptide derived from human c-Abl isoform b immunogen: around the phosphorylation site of Tyr276 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: The c Abl proto oncogene encodes a protein tyrosine kinase that is located in the Product Detail: cytoplasm and nucleus.
    [Show full text]
  • RAD9A Rabbit Pab
    Leader in Biomolecular Solutions for Life Science RAD9A Rabbit pAb Catalog No.: A1890 Basic Information Background Catalog No. This gene product is highly similar to Schizosaccharomyces pombe rad9, a cell cycle A1890 checkpoint protein required for cell cycle arrest and DNA damage repair. This protein possesses 3' to 5' exonuclease activity, which may contribute to its role in sensing and Observed MW repairing DNA damage. It forms a checkpoint protein complex with RAD1 and HUS1. This 60kDa complex is recruited by checkpoint protein RAD17 to the sites of DNA damage, which is thought to be important for triggering the checkpoint-signaling cascade. Alternatively Calculated MW spliced transcript variants encoding different isoforms have been found for this gene. 42kDa Category Primary antibody Applications WB, IHC, IF Cross-Reactivity Human, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 5883 Q99638 IHC 1:50 - 1:200 Immunogen 1:50 - 1:200 IF Recombinant fusion protein containing a sequence corresponding to amino acids 162-391 of human RAD9A (NP_004575.1). Synonyms RAD9A;RAD9 Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using RAD9A antibody (A1890) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Immunohistochemistry of paraffin- Immunohistochemistry of paraffin- Immunofluorescence analysis of MCF-7 embedded rat liver using RAD9A antibody embedded human liver damage using cells using RAD9A antibody (A1890).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.873,482 B2 Stefanon Et Al
    US007873482B2 (12) United States Patent (10) Patent No.: US 7.873,482 B2 Stefanon et al. (45) Date of Patent: Jan. 18, 2011 (54) DIAGNOSTIC SYSTEM FOR SELECTING 6,358,546 B1 3/2002 Bebiak et al. NUTRITION AND PHARMACOLOGICAL 6,493,641 B1 12/2002 Singh et al. PRODUCTS FOR ANIMALS 6,537,213 B2 3/2003 Dodds (76) Inventors: Bruno Stefanon, via Zilli, 51/A/3, Martignacco (IT) 33035: W. Jean Dodds, 938 Stanford St., Santa Monica, (Continued) CA (US) 90403 FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 WO WO99-67642 A2 12/1999 U.S.C. 154(b) by 158 days. (21)21) Appl. NoNo.: 12/316,8249 (Continued) (65) Prior Publication Data Swanson, et al., “Nutritional Genomics: Implication for Companion Animals'. The American Society for Nutritional Sciences, (2003).J. US 2010/O15301.6 A1 Jun. 17, 2010 Nutr. 133:3033-3040 (18 pages). (51) Int. Cl. (Continued) G06F 9/00 (2006.01) (52) U.S. Cl. ........................................................ 702/19 Primary Examiner—Edward Raymond (58) Field of Classification Search ................... 702/19 (74) Attorney, Agent, or Firm Greenberg Traurig, LLP 702/23, 182–185 See application file for complete search history. (57) ABSTRACT (56) References Cited An analysis of the profile of a non-human animal comprises: U.S. PATENT DOCUMENTS a) providing a genotypic database to the species of the non 3,995,019 A 1 1/1976 Jerome human animal Subject or a selected group of the species; b) 5,691,157 A 1 1/1997 Gong et al.
    [Show full text]
  • Differential Expression Profile Analysis of DNA Damage Repair Genes in CD133+/CD133‑ Colorectal Cancer Cells
    ONCOLOGY LETTERS 14: 2359-2368, 2017 Differential expression profile analysis of DNA damage repair genes in CD133+/CD133‑ colorectal cancer cells YUHONG LU1*, XIN ZHOU2*, QINGLIANG ZENG2, DAISHUN LIU3 and CHANGWU YUE3 1College of Basic Medicine, Zunyi Medical University, Zunyi; 2Deparment of Gastroenterological Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi;3 Zunyi Key Laboratory of Genetic Diagnosis and Targeted Drug Therapy, The First People's Hospital of Zunyi, Zunyi, Guizhou 563003, P.R. China Received July 20, 2015; Accepted January 6, 2017 DOI: 10.3892/ol.2017.6415 Abstract. The present study examined differential expression cells. By contrast, 6 genes were downregulated and none levels of DNA damage repair genes in COLO 205 colorectal were upregulated in the CD133+ cells compared with the cancer cells, with the aim of identifying novel biomarkers for COLO 205 cells. These findings suggest that CD133+ cells the molecular diagnosis and treatment of colorectal cancer. may possess the same DNA repair capacity as COLO 205 COLO 205-derived cell spheres were cultured in serum-free cells. Heterogeneity in the expression profile of DNA damage medium supplemented with cell factors, and CD133+/CD133- repair genes was observed in COLO 205 cells, and COLO cells were subsequently sorted using an indirect CD133 205-derived CD133- cells and CD133+ cells may therefore microbead kit. In vitro differentiation and tumorigenicity assays provide a reference for molecular diagnosis, therapeutic target in BABA/c nude mice were performed to determine whether selection and determination of the treatment and prognosis for the CD133+ cells also possessed stem cell characteristics, in colorectal cancer.
    [Show full text]
  • Alterations of the Interactome of Bcl-2 Proteins in Breast Cancer at the Transcriptional, Mutational and Structural Level
    RESEARCH ARTICLE Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level Simon Mathis Kønig1, Vendela Rissler1, Thilde Terkelsen1, Matteo Lambrughi1, 1,2 Elena PapaleoID * 1 Computational Biology Laboratory, Danish Cancer Society Research Center, Copenhagen, Denmark, a1111111111 2 Translational Disease Systems Biology, Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Protein Research University of Copenhagen, Copenhagen, Denmark a1111111111 a1111111111 * [email protected] a1111111111 a1111111111 Abstract Apoptosis is an essential defensive mechanism against tumorigenesis. Proteins of the B- OPEN ACCESS cell lymphoma-2 (Bcl-2) family regulate programmed cell death by the mitochondrial apopto- sis pathway. In response to intracellular stress, the apoptotic balance is governed by inter- Citation: Kønig SM, Rissler V, Terkelsen T, Lambrughi M, Papaleo E (2019) Alterations of the actions of three distinct subgroups of proteins; the activator/sensitizer BH3 (Bcl-2 homology interactome of Bcl-2 proteins in breast cancer at 3)-only proteins, the pro-survival, and the pro-apoptotic executioner proteins. Changes in the transcriptional, mutational and structural level. expression levels, stability, and functional impairment of pro-survival proteins can lead to an PLoS Comput Biol 15(12): e1007485. https://doi. imbalance in tissue homeostasis. Their overexpression or hyperactivation can result in org/10.1371/journal.pcbi.1007485 oncogenic effects. Pro-survival Bcl-2 family members carry out their function by binding the Editor: Igor N. Berezovsky, A�STAR Singapore, BH3 short linear motif of pro-apoptotic proteins in a modular way, creating a complex net- SINGAPORE work of protein-protein interactions. Their dysfunction enables cancer cells to evade cell Received: July 8, 2019 death.
    [Show full text]
  • Bioinformatics Analysis to Screen Key Genes in Papillary Thyroid Carcinoma
    ONCOLOGY LETTERS 19: 195-204, 2020 Bioinformatics analysis to screen key genes in papillary thyroid carcinoma YUANHU LIU1*, SHUWEI GAO2*, YAQIONG JIN2, YERAN YANG2, JUN TAI1, SHENGCAI WANG1, HUI YANG2, PING CHU2, SHUJING HAN2, JIE LU2, XIN NI1,2, YONGBO YU2 and YONGLI GUO2 1Department of Otolaryngology, Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; 2Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, MOE Key Laboratory of Major Diseases in Children, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, P.R. China Received April 22, 2019; Accepted September 24, 2019 DOI: 10.3892/ol.2019.11100 Abstract. Papillary thyroid carcinoma (PTC) is the most verifying their potential for clinical diagnosis. Taken together, common type of thyroid carcinoma, and its incidence has the findings of the present study suggest that these genes and been on the increase in recent years. However, the molecular related pathways are involved in key events of PTC progression mechanism of PTC is unclear and misdiagnosis remains a and facilitate the identification of prognostic biomarkers. major issue. Therefore, the present study aimed to investigate this mechanism, and to identify key prognostic biomarkers. Introduction Integrated analysis was used to explore differentially expressed genes (DEGs) between PTC and healthy thyroid tissue. To Thyroid carcinoma is the most common malignancy of investigate the functions and pathways associated with DEGs, the head and neck, and accounts for 91.5% of all endocrine Gene Ontology, pathway and protein-protein interaction (PPI) malignancies (1).
    [Show full text]
  • And Right-Sided Colon Cancer Wangxiong Hu1, Yanmei Yang2, Xiaofen Li1,3, Minran Huang1, Fei Xu1, Weiting Ge1, Suzhan Zhang1,4, and Shu Zheng1,4
    Published OnlineFirst November 29, 2017; DOI: 10.1158/1541-7786.MCR-17-0483 Genomics Molecular Cancer Research Multi-omics Approach Reveals Distinct Differences in Left- and Right-Sided Colon Cancer Wangxiong Hu1, Yanmei Yang2, Xiaofen Li1,3, Minran Huang1, Fei Xu1, Weiting Ge1, Suzhan Zhang1,4, and Shu Zheng1,4 Abstract Increasing evidence suggests that left-sided colon cancer determined between LCC and RCC. Especially for Prostate (LCC) and right-sided colon cancer (RCC) are emerging as two Cancer Susceptibility Candidate 1 (PRAC1), a gene that was different colorectal cancer types with distinct clinical character- closely associated with hypermethylation, was the top signif- istics. However, the discrepancy in the underlying molecular icantly downregulated gene in RCC. Multi-omics comparison event between these types of cancer has not been thoroughly of LCC and RCC suggests that there are more aggressive markers elucidated to date and warrants comprehensive investigation. in RCC and that tumor heterogeneity occurs within the loca- To this end, an integrated dataset from The Cancer Genome tion-based subtypes of colon cancer. These results clarify the Atlas was used to compare and contrast LCC and RCC, covering debate regarding the conflicting prognosis between LCC and mutation, DNA methylation, gene expression, and miRNA. RCC, as proposed by different studies. Briefly, the signaling pathway cross-talk is more prevalent in RCC than LCC, such as RCC-specific PI3K pathway, which often Implications: The underlying molecular features present in LCC exhibits cross-talk with the RAS and P53 pathways. Meanwhile, and RCC identified in this study are beneficial for adopting methylation signatures revealed that RCC was hypermethylated reasonable therapeutic approaches to prolong overall survival relative to LCC.
    [Show full text]
  • Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer
    Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/).
    [Show full text]
  • Supplementary,Figure,1 Supplementary Figure 1
    A B A2058 (BRAF*) IMR90 3 +700% 5 +2400% % change vs. day 0 % change vs. day 0 ! DT$$$V$$$DTV ! DT$$E$$DTE 4 +1500% p!ERK 2 +300% p!ERK 3 +700% ERK ERK 2 +300% H3K9Ac 1 +100% H3K9Ac (day3 vs. day 0) (day 3 vs. day ) 1 +100% H3 H3 0 0 0 0 DMSO DT V DT+V DMSO DT ENT DT+ENT log2 fold change in cell number log2 fold change in cell number C D E Hs695THs695T Hs695T 2.040 2.0 Hs695T DMSODMSO NIH3T3 DMSO 293T 1.5 1.5 2.0 MEKi+BRAFi DTDT 5 +3100% 30 4 +1500% % change vs. day 0 DMSO % change vs. day 0 1.0 1.0 HDACi E E 4 +1500% 1.5 0.5 MEKi+BRAFi+HDACi DT 3 +700% 0.520 DTEDTE 3 +700% 0.0 1.0 E 20 40 60 0.080 2 +300% log2 fold growth -0.5 10 20 40 60 80 2 +300% hours of treatment 0.5 DTE log2 fold growth -0.5 -1.0 hours of treatment 1 +100% 1 +100% (day3 vs. day 0) (day3 vs. day 0) -1.00 0.0 0 0 0 20 2040 4060 8060 80 0 0 DMSO DT ENT DT+ENT Caspase 3/7 positive cells (%) DMSO DT ENT DT+ENT log2 fold growth -0.5hours of treatment log2 fold change in cell number hours of treatment log2 fold change in cell number -1.0 F G A2058'(high'MITF) SKMEL5'(high'MITF) Resistant Sensitive High'MITFMITF Expression 4.5 4.0 3.5 3.0 2.5 DMSO MEKi VOR ENT MEKi+VOR MEKi+ENT DMSO MEKi VOR ENT MEKi+VOR MEKi+ENT 2.0 1.5 MITF MITF 1.0 0.5 Low'MITF Vinculin Vinculin 0.4 0.3 0.10 RPMI7951'(low'MITF) Hs695T'(low'MITF) 0.08 Resistant Sensitive 0.06 0.04 Relative MITF expression (MITF/Actin) 0.02 0.00 DMSO MEKi VOR ENT MEKi+VOR MEKi+ENT DMSO MEKi VOR ENT MEKi+VOR MEKi+ENT A375 A2058 MEWO A101D Hs695T SKMEL5 SKMEL2 LOXIMVI MITF MITF UACC257 MALME3MRPMI7951 Vinculin Vinculin sensitive resistant H Hs695T ! E$$$$$$DTE HDAC1 HDAC2 HDAC3 GAPDH Supplementary,Figure,1 Supplementary Figure 1.
    [Show full text]